- Home
- SMSI vs TENX Comparison
SMSI vs TENX Comparison
Compare SMSI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMSI
- TENX
- Stock Information
- Founded
- SMSI 1982
- TENX 1967
- Country
- SMSI United States
- TENX United States
- Employees
- SMSI N/A
- TENX N/A
- Industry
- SMSI Computer Software: Prepackaged Software
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- SMSI Technology
- TENX Health Care
- Exchange
- SMSI Nasdaq
- TENX Nasdaq
- Market Cap
- SMSI 24.7M
- TENX 21.6M
- IPO Year
- SMSI 1995
- TENX N/A
- Fundamental
- Price
- SMSI $0.91
- TENX $5.62
- Analyst Decision
- SMSI Strong Buy
- TENX Strong Buy
- Analyst Count
- SMSI 1
- TENX 3
- Target Price
- SMSI $5.00
- TENX $16.00
- AVG Volume (30 Days)
- SMSI 144.0K
- TENX 12.8K
- Earning Date
- SMSI 05-07-2025
- TENX 05-20-2025
- Dividend Yield
- SMSI N/A
- TENX N/A
- EPS Growth
- SMSI N/A
- TENX N/A
- EPS
- SMSI N/A
- TENX N/A
- Revenue
- SMSI $19,378,000.00
- TENX N/A
- Revenue This Year
- SMSI $36.40
- TENX N/A
- Revenue Next Year
- SMSI $46.07
- TENX N/A
- P/E Ratio
- SMSI N/A
- TENX N/A
- Revenue Growth
- SMSI N/A
- TENX N/A
- 52 Week Low
- SMSI $0.52
- TENX $2.77
- 52 Week High
- SMSI $2.90
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- SMSI 46.04
- TENX 51.01
- Support Level
- SMSI $0.91
- TENX $5.49
- Resistance Level
- SMSI $1.09
- TENX $5.87
- Average True Range (ATR)
- SMSI 0.08
- TENX 0.26
- MACD
- SMSI -0.01
- TENX 0.04
- Stochastic Oscillator
- SMSI 1.82
- TENX 62.59
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. It offers multi-platform, modular solutions such as SafePath; CommSuite; and ViewSpot. The company's only reportable segment is Wireless. Its Wireless segment sells to large wireless carriers, cable operators, and OEMs.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.